+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05382559

Phase 1 Study of ASP3082 for Advanced Solid Tumors With KRAS G12D Mutation Evaluating Safety and Dose

Led by Astellas Pharma Inc · Updated on 2026-10-14

681

Participants Needed

68

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ASP3082 in adults with advanced or metastatic solid tumors that have a KRAS G12D mutation. This Phase 1 open-label study aims to assess how safe and tolerable ASP3082 is when given alone or with other treatments like cetuximab. The study includes people who have received prior standard therapies or are ineligible for them, focusing on determining appropriate doses and treatment combinations. The study is divided into two parts. In Part 1, small groups of participants receive increasing doses of ASP3082 alone or with cetuximab through intravenous infusion in 21-day cycles to find suitable dosing levels. In Part 2, participants receive ASP3082 alone or combined with other therapies such as FOLFIRINOX, Nab-paclitaxel plus gemcitabine, docetaxel, pembrolizumab, platinum-based chemotherapy with pemetrexed, or NALIRIFOX, with dosing based on Part 1 findings. Treatment continues until intolerable side effects, disease progression, starting other cancer treatments, or participant decision to stop. Participants will undergo regular assessments including monitoring for side effects, laboratory tests, electrocardiograms, physical exams, and performance status evaluations for up to 48 months. Researchers will measure dose-limiting toxicities, adverse events, and tumor response using standard criteria. Tumor samples will be collected before and during treatment to assess KRAS G12D changes. The study monitors safety and treatment effects closely throughout participation, which may last several years.

CONDITIONS

Brief Title

A Study of ASP3082 in Adults With Advanced Solid Tumors

Research Team

A

Astellas Pharma Global Development, Inc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here